(Q42944301)

11 November 2017

title

Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment (English)

1 reference

11 November 2017

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment (English)

1 reference

10.2165/11534330-000000000-00000

Crossref

DOI

https://api.crossref.org/works/10.2165/11534330-000000000-00000

17 June 2024

1 reference

Angelika Weil

1

1 reference

11 November 2017

Paul Martin

2

1 reference

11 November 2017

Robert Smith

3

1 reference

11 November 2017

Stuart Oliver

4

1 reference

11 November 2017

Peter Langmuir

5

1 reference

11 November 2017

Jessica Read

6

1 reference

11 November 2017

Karl-Heinz Molz

7

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20690783

17 June 2024

publication date

1 September 2010

1 reference

Clinical Pharmacokinetics

11 November 2017

published in

1 reference

11 November 2017

volume

49

1 reference

11 November 2017

issue

9

1 reference

11 November 2017

page(s)

607-618

1 reference

https://scigraph.springernature.com/pub.10.2165/11534330-000000000-00000

11 November 2017

exact match

0 references

cites work

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

1 reference

12 December 2020

Drug dosing in chronic kidney disease

1 reference

12 December 2020

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Dose adjustment in patients with liver disease

1 reference

12 December 2020

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

1 reference

12 December 2020

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

1 reference

12 December 2020

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

1 reference

12 December 2020

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Transection of the oesophagus for bleeding oesophageal varices

1 reference

12 December 2020

Cytotoxic anticancer agents and renal impairment study: the challenge remains

1 reference

12 December 2020

Pharmacokinetics of anticancer agents in patients with impaired liver function

1 reference

12 December 2020

The effect of chronic renal failure on drug metabolism and transport

1 reference

12 December 2020

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

1 reference

12 December 2020

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function

1 reference

12 December 2020

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

12 December 2020

10.2165/11534330-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

11 November 2017

1007028044

0 references

1 reference